Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRONTSE:GUDNYSE:RIVBATS:WEED On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRONCronos Group$2.04+0.7%$1.86$1.60▼$2.66$784.30M1.061.30 million shs552,738 shsGUDKnight TherapeuticsC$5.79+0.5%C$5.85C$5.09▼C$6.45C$585.66M0.563,295 shs7,174 shsRIVRiverNorth Opportunities Fund$12.02+0.6%$11.49$10.11▼$12.96N/AN/A81,893 shs44,679 shsWEEDRoundhill Cannabis ETF$10.58-16.7%$10.89$8.79▼$35.37$4.41M1.149,920 shs4,713 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRONCronos Group+1.00%-2.42%+10.38%+1.00%-24.63%GUDKnight Therapeutics-0.69%0.00%-2.70%+4.54%-2.87%RIVRiverNorth Opportunities Fund-0.58%+0.17%+5.48%-2.37%-1.73%WEEDRoundhill Cannabis ETF+0.90%-2.81%-7.42%-24.63%-69.41%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRONCronos Group1.6375 of 5 stars0.05.00.00.03.40.01.3GUDKnight Therapeutics1.4932 of 5 stars2.80.00.00.00.63.30.6RIVRiverNorth Opportunities FundN/AN/AN/AN/AN/AN/AN/AN/AWEEDRoundhill Cannabis ETFN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRONCronos Group 0.00N/AN/AN/AGUDKnight Therapeutics 3.50Strong BuyC$7.1523.49% UpsideRIVRiverNorth Opportunities Fund 0.00N/AN/AN/AWEEDRoundhill Cannabis ETF 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest RIV, CRON, GUD, and WEED Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/9/2025GUDKnight TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetHold ➝ BuyC$6.503/25/2025GUDKnight TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuyC$6.25 ➝ C$7.453/21/2025GUDKnight TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold3/11/2025GUDKnight TherapeuticsResearch CapitlSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRONCronos Group$124.59M6.30N/AN/A$2.87 per share0.71GUDKnight TherapeuticsC$348.70M1.68C$1.51 per share3.85C$7.65 per share0.76RIVRiverNorth Opportunities Fund$44.13MN/AN/AN/AN/AN/AWEEDRoundhill Cannabis ETFN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRONCronos Group-$73.96M$0.13N/A67.831.74-42.65%-2.56%-2.47%8/14/2025 (Estimated)GUDKnight Therapeutics-C$30.73M-C$0.30N/A∞N/A-8.81%-4.04%0.51%N/ARIVRiverNorth Opportunities FundN/AN/A0.00∞N/AN/AN/AN/AN/AWEEDRoundhill Cannabis ETFN/AN/A0.00∞N/AN/AN/AN/AN/ALatest RIV, CRON, GUD, and WEED EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025CRONCronos Group$0.01$0.02+$0.01$0.02$45.44 million$33.62 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRONCronos GroupN/AN/AN/AN/AN/AGUDKnight TherapeuticsN/AN/AN/AN/AN/ARIVRiverNorth Opportunities Fund$1.6613.82%-8.84%N/AN/AWEEDRoundhill Cannabis ETFN/AN/AN/AN/AN/ALatest RIV, CRON, GUD, and WEED DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/4/2025RIVRiverNorth Opportunities Fundmonthly$0.127713%6/13/20256/13/20256/30/20254/3/2025RIVRiverNorth Opportunities Fundmonthly$0.127713%6/13/20256/13/20256/30/20255/13/2025RIVRiverNorth Opportunities Fund$0.127712.72%5/15/20255/16/20255/30/20254/9/2025RIVRiverNorth Opportunities Fund$0.127714.71%4/15/20254/16/20254/30/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRONCronos GroupN/A24.2423.05GUDKnight Therapeutics7.523.361.79RIVRiverNorth Opportunities FundN/AN/AN/AWEEDRoundhill Cannabis ETFN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRONCronos Group8.71%GUDKnight Therapeutics12.58%RIVRiverNorth Opportunities FundN/AWEEDRoundhill Cannabis ETFN/AInsider OwnershipCompanyInsider OwnershipCRONCronos Group7.30%GUDKnight Therapeutics45.62%RIVRiverNorth Opportunities FundN/AWEEDRoundhill Cannabis ETFN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRONCronos Group450385.41 million356.14 millionOptionableGUDKnight Therapeutics725101.15 millionN/ANot OptionableRIVRiverNorth Opportunities FundN/AN/AN/ANot OptionableWEEDRoundhill Cannabis ETFN/A345,000N/ANot OptionableRIV, CRON, GUD, and WEED HeadlinesRecent News About These Companies7 Best Marijuana Stocks and ETFs to Buy in 2025May 12, 2025 | money.usnews.com6 Best-Performing ETFs of Last WeekApril 21, 2025 | zacks.comRoundhill COIN WeeklyPay ETF (COIW)April 3, 2025 | uk.investing.comBest & Worst ETF Zones of Q1March 31, 2025 | zacks.comWhen (WEED) Moves Investors should ListenJanuary 19, 2025 | news.stocktradersdaily.com(WEED) Pivots Trading Plans and Risk ControlsJanuary 9, 2025 | news.stocktradersdaily.comTop & Flop ETFs of 2024December 31, 2024 | zacks.com(WEED) Long Term Investment AnalysisDecember 19, 2024 | news.stocktradersdaily.com(WEED) Trading AdviceNovember 27, 2024 | news.stocktradersdaily.com(WEED) Investment AnalysisNovember 17, 2024 | news.stocktradersdaily.com(WEED) Investment ReportOctober 26, 2024 | news.stocktradersdaily.com(WEED) Trading SignalsOctober 4, 2024 | news.stocktradersdaily.comWEED Roundhill Cannabis ETFOctober 4, 2024 | seekingalpha.com(WEED) Trading ReportSeptember 24, 2024 | news.stocktradersdaily.comRoundhill ETF Trust Roundhill Small Cap 0DTE Covered Call Strategy ETF (BATS:RDTE) Quotes, Forecast and News SummarySeptember 20, 2024 | benzinga.comRoundhill Magnificent Seven ETF (NASDAQ:MAGS), Short Interest ReportSeptember 9, 2024 | benzinga.com$1B In 26 Days: This Marijuana Company Is Capitalizing On Ohio's Cannabis SurgeSeptember 7, 2024 | benzinga.comYBTC Sep 2024 43.000 put (YBTC240920P00043000)August 20, 2024 | finance.yahoo.comLong Term Trading Analysis for (WEED)August 19, 2024 | news.stocktradersdaily.comQDTE Aug 2024 42.000 put (QDTE240816P00042000)July 30, 2024 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesQuantum Stocks Skyrocket, Led by IonQ's NVIDIA DeclarationBy Leo Miller | May 27, 2025View Quantum Stocks Skyrocket, Led by IonQ's NVIDIA DeclarationTesla: Why Analysts Think It Could Jump Another 47%By Sam Quirke | May 27, 2025View Tesla: Why Analysts Think It Could Jump Another 47%MercadoLibre Is Soaring—Should You Wait for a Better Entry?By Ryan Hasson | May 26, 2025View MercadoLibre Is Soaring—Should You Wait for a Better Entry?Alphabet Stock Lags—But Waymo May Be Its Hidden DriverBy Gabriel Osorio-Mazilli | May 25, 2025View Alphabet Stock Lags—But Waymo May Be Its Hidden Driver3 Underrated Stocks Quietly Delivering Big GainsBy Thomas Hughes | May 13, 2025View 3 Underrated Stocks Quietly Delivering Big GainsRIV, CRON, GUD, and WEED Company DescriptionsCronos Group NASDAQ:CRON$2.04 +0.02 (+0.74%) As of 01:11 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.Knight Therapeutics TSE:GUDC$5.79 +0.03 (+0.52%) As of 12:42 PM EasternKnight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma. The company provides Ladecvina for multiple myeloma and myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Palbocil for breast cancer; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Dolufevir for HIV infection; Exelon for dementia; and Ibsrela for irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for vasomotor symptoms; Fibridoner for idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, it finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is headquartered in Montreal, Canada.RiverNorth Opportunities Fund NYSE:RIV$12.02 +0.08 (+0.63%) As of 01:10 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.RiverNorth Opportunities Fund, Inc. is a close ended equity mutual fund co- launched and co- managed by ALPS Advisors, Inc. and RiverNorth Capital Management, LLC. It invests in the equity markets. The fund seeks to invest in stocks of companies operating across the diversified sectors. RiverNorth Opportunities Fund, Inc. was formed on December 24, 2015 and is domiciled in the United States.Roundhill Cannabis ETF BATS:WEED$10.58 -2.13 (-16.74%) As of 01:12 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.The Roundhill Cannabis ETF (WEED) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed portfolio of equities and total return swaps that provide exposure to the global cannabis and hemp ecosystem. WEED was launched on Apr 20, 2022 and is managed by Roundhill. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Salesforce’s Stock Price Presents an Opportunity to Buy NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s Why Goodyear Stock Surges 28% in 2025: Is More Growth Ahead? Intel's Loss Is Broadcom's Gain as AVGO Dominates Networking Target's Big Bet: Is It a Cheap Stock or a Value Trap? Dividend Investors Looking for an Edge? 3 Stocks Insiders Bought Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock GameStop Buys Bitcoin: Smart Strategy or Big Mistake? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
